AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
|Articles|November 1, 2015
In one word: what drew you to dermatology?
Dermatology Times invited you to share the one driving reason you entered the field of dermatology. You told us, and we listened. Here are the results.
Advertisement
The size of each word in the cloud reflects how frequently it was entered.
Dermatology Times invited you to share the one driving reason you entered the field of dermatology. You told us, and we listened. Here are the results.
Advertisement
Related to this article
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
Advertisement
Advertisement
Trending on Dermatology Times
1
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
2
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
3
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
4
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
5